MX2020013205A - Composiciones y metodos para el diagnostico y tratamiento de cancer. - Google Patents

Composiciones y metodos para el diagnostico y tratamiento de cancer.

Info

Publication number
MX2020013205A
MX2020013205A MX2020013205A MX2020013205A MX2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A MX 2020013205 A MX2020013205 A MX 2020013205A
Authority
MX
Mexico
Prior art keywords
diagnosis
treatment
cancer
compositions
methods
Prior art date
Application number
MX2020013205A
Other languages
English (en)
Spanish (es)
Inventor
Markus Fiedler
Joycelyn Wüstehube-Lausch
Matin Daneschdar
Ugur Sahin
Bonny Gaby Lui
Nadja Salomon
Hans - Ulrich Schmoldt
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2020013205A publication Critical patent/MX2020013205A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
MX2020013205A 2018-06-08 2019-06-06 Composiciones y metodos para el diagnostico y tratamiento de cancer. MX2020013205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2018/065205 WO2019233605A1 (en) 2018-06-08 2018-06-08 Compositions and methods for diagnosis and treatment of cancer
PCT/EP2019/064872 WO2019234190A1 (en) 2018-06-08 2019-06-06 Compositions and methods for diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
MX2020013205A true MX2020013205A (es) 2021-02-26

Family

ID=62636178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013205A MX2020013205A (es) 2018-06-08 2019-06-06 Composiciones y metodos para el diagnostico y tratamiento de cancer.

Country Status (10)

Country Link
US (2) US11673939B2 (https=)
EP (1) EP3802585A1 (https=)
JP (1) JP7466466B2 (https=)
KR (2) KR20240142617A (https=)
CN (2) CN112424220A (https=)
AU (1) AU2019282316B2 (https=)
BR (1) BR112020024034A2 (https=)
CA (1) CA3101246A1 (https=)
MX (1) MX2020013205A (https=)
WO (2) WO2019233605A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111302A1 (en) 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CA2741040C (en) * 2008-10-20 2015-09-22 Gwangju Institute Of Science And Technology Bipodal-peptide binder
CA2822938A1 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
AU2014252354A1 (en) * 2013-04-11 2015-11-19 Merck Patent Gmbh Potent inhibitors of human matriptase derived from McotI-II variants
WO2016022597A1 (en) * 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
JP2021526808A (ja) 2021-10-11
JP7466466B2 (ja) 2024-04-12
EP3802585A1 (en) 2021-04-14
US20210246191A1 (en) 2021-08-12
CN116987180A (zh) 2023-11-03
WO2019233605A1 (en) 2019-12-12
KR20210020006A (ko) 2021-02-23
BR112020024034A2 (pt) 2021-02-23
CA3101246A1 (en) 2019-12-12
US20240002471A1 (en) 2024-01-04
CN112424220A (zh) 2021-02-26
WO2019234190A1 (en) 2019-12-12
NZ770391A (en) 2024-09-27
KR20240142617A (ko) 2024-09-30
US11673939B2 (en) 2023-06-13
AU2019282316A1 (en) 2020-12-24
US12516104B2 (en) 2026-01-06
AU2019282316B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
JOP20200142A1 (ar) بنيات rnai لتثبيط التعبير عن pnpla3 وطرق استخدامها
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CR20170060A (es) Anticuerpos anti tigit
MX374126B (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada.
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
CO2019012329A2 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
GT201200123A (es) Nuevo uso antitumoral de cabazitaxel
MX2017000168A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
MX2016012933A (es) Composiciones de relleno de tejidos y metodos de uso.
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
UY33174A (es) Anticuerpo monoclonal anti-factor de necrosis tumoral (tnf), secuencias que lo definen, composiciones que lo comprenden y sus aplicaciones
BR112016013157A2 (pt) peptídeos resistentes à protease
MX384421B (es) Ésteres de oxaborol y sus usos.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2020013205A (es) Composiciones y metodos para el diagnostico y tratamiento de cancer.